Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02618889 · ClinicalTrials.gov registry record · Phase 4
OnabotulinumtoxinA in the Management of Psychogenic Dystonia
A Phase 4 study of Torticollis, Dystonia, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT02618889 is a Phase 4 study of Torticollis, Dystonia that has completed, run by University of Cincinnati. The registered enrollment target is 18 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02618889, a Phase 4 study of Torticollis, Dystonia, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to evaluate if patients with psychogenic dystonia treated with onabotulinumtoxinA (BOTOX) injections will demonstrate lower severity and disability at one month and at three months than those having received placebo injections
Conditions Studied
Interventions
- BEHAVIORAL CBT
Study Locations (1)
Ohio
- Alberto Espay - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-01-15 |
| Est. Completion | 2017-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02618889
The ClinicalTrials.gov registry entry for NCT02618889 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Torticollis, Dystonia appearing as the primary indexed condition, and to 1 intervention - of which CBT is the first listed.
NCT02618889 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT02618889 about?
NCT02618889 is a clinical study titled "OnabotulinumtoxinA in the Management of Psychogenic Dystonia". The purpose of this research study is to evaluate if patients with psychogenic dystonia treated with onabotulinumtoxinA (BOTOX) injections will demonstrate lower severity and disability at one month and at three months than those having received placebo injections
What is the current status of trial NCT02618889?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2016-01-15. Estimated completion is 2017-06-30.
What conditions does trial NCT02618889 study?
This clinical trial studies the following conditions: Torticollis, Dystonia.
What interventions are being tested in trial NCT02618889?
The interventions under investigation include: CBT (BEHAVIORAL).
Who is sponsoring clinical trial NCT02618889?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02618889 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.